Trial · NCT06928766
Effects of Eszopiclone and Lemborexant in People With OSA With a Low Arousal Threshold Who Have Difficulty Sleeping
NCT06928766, Phase 2, Recruiting, Flinders University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Eszopiclone and Lemborexant in People With OSA With a Low Arousal Threshold Who Have Difficulty Sleeping. Trials, record NCT06928766. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06928766
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Eszopiclone and Lemborexant in People With OSA With a Low Arousal Threshold Who Have Difficulty Sleeping
- NCT number
- NCT06928766
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 15 participants, estimated
- Lead sponsor
- Flinders University
- Conditions
- OSA - Obstructive Sleep Apnea
- Interventions
- Eszopiclone 3 mg, Placebo, Lemborexant 10mg
- First posted
- 2025-04-15
- Last updated
- 2026-09-02
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in OSA severity (eszopiclone and lemborexant night vs. placebo night) | Two non-consecutive single night sleep studies (eszopiclone and lemborexant night vs. placebo night) up to one month apart. | OSA severity as measured by the apnoea hypopnea index (units: number of respiratory events/h sleep) during overnight in-laboratory polysomnography. |
| Secondary | Change in nadir overnight hypoxemia (eszopiclone and lemborexant night vs. placebo night) | Two non-consecutive single night sleep studies (eszopiclone and lemborexant night vs. placebo night) up to one month apart. | Nadir overnight oxygen saturation during sleep (units: %) measured via pulse oximetry during overnight in-laboratory polysomnography. |
| Secondary | Change in mean overnight hypoxemia (eszopiclone and lemborexant night vs. placebo night) | Two non-consecutive single night sleep studies (eszopiclone and lemborexant night vs. placebo night) up to one month apart. | Mean overnight oxygen saturation during sleep (units: %) measured via pulse oximetry during overnight in-laboratory polysomnography. |
| Secondary | Change in time below 90% blood arterial oxygen saturation (eszopiclone and lemborexant night vs. placebo night) | Two non-consecutive single night sleep studies (eszopiclone and lemborexant night vs. placebo night) up to one month apart. | Percent time asleep spent below an arterial oxygen saturation of 90% measured via pulse oximetry during overnight in-laboratory polysomnography. |
| Secondary | Change in sleep efficiency (eszopiclone and lemborexant night vs. placebo night) | Two non-consecutive single night sleep studies (eszopiclone and lemborexant night vs. placebo night) up to one month apart. | Percent time spent asleep divided by the recording time from lights out to lights on during overnight in-laboratory polysomnography |
| Secondary | Change in arousal index (eszopiclone and lemborexant night vs. placebo night) | Two non-consecutive single night sleep studies (eszopiclone and lemborexant night vs. placebo night) up to one month apart. | Number of cortical arousals per hour of sleep during overnight in-laboratory polysomnography. |
| Secondary | Change in respiratory control (eszopiclone and lemborexant night vs. placebo night) | Two non-consecutive single night sleep studies (eszopiclone and lemborexant night vs. placebo night) up to one month apart. | Loop gain and the ventilatory response to arousal (units: % eupnea) during overnight in-laboratory polysomnography. |
| Secondary | Change in the respiratory arousal threshold (eszopiclone and lemborexant night vs. placebo night) | Two non-consecutive single night sleep studies (eszopiclone and lemborexant night vs. placebo night) up to one month apart. | Threshold to arousal (units: % eupnea) during overnight in-laboratory polysomnography. |
| Secondary | Change in airway collapsibility (eszopiclone and lemborexant night vs. placebo night) | Two non-consecutive single night sleep studies (eszopiclone and lemborexant night vs. placebo night) up to one month apart. | Vpassive (units: % eupnea) during overnight in-laboratory polysomnography. |
| Secondary | Change in pharyngeal muscle response (eszopiclone and lemborexant night vs. placebo night) | Two non-consecutive single night sleep studies (eszopiclone and lemborexant night vs. placebo night) up to one month apart. | Vcompensation (units: % eupnea) during overnight in-laboratory polysomnography. |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers29
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Psychomotor Vigilance Task | Secondary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06928766
GET https://conductscience.org/api/trials/v1/NCT06928766/papers?page=2